MIRA
INFORM REPORT
|
Report Date : |
06.08.2008 |
IDENTIFICATION
DETAILS
|
Name : |
AKUMS DRUGS AND PHARMACEUTICALS LIMITED |
|
|
|
|
Registered Office : |
304, Mohan Place, LSC Block – C, Saraswati Vihar, New Delhi – 110 034, |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as on) : |
31.03.2007 |
|
|
|
|
Date of Incorporation : |
19.04.2004 |
|
|
|
|
Com. Reg. No.: |
55-125888 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24239DL2004PLC125888 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
DELA13882B |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAECA7090B |
|
|
|
|
Legal Form : |
A Closely held Public Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturer and Supplier of Pharmaceutical Machinery. |
RATING &
COMMENTS
|
MIRA’s Rating : |
Aa |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
Maximum Credit Limit : |
USD 4200000 |
|
|
|
|
Status : |
Very Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well – established and reputed company having
satisfactory track. Trade relations are fair. General financial position is satisfactory.
Payments are usually correct and as per commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
LOCATIONS
|
Registered Office : |
304, Mohan Place, LSC Block – C, Saraswati Vihar, New Delhi – 110 034,
India |
|
Tel. No.: |
91-11-27011428 / 27011315/18/21 |
|
Fax No.: |
91-11-27023256 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Factory - 1 [ORAL DOSAGE FORM] : |
19-20-21, Sec-6A, I.I.E., SIDCUL, Ranipur,
Haridwar-249403, Uttarakhand INDIA |
|
Tel. No.: |
91-1334-239220 – 24, 325984, 5,6 |
|
Fax No.: |
91-1334-239219 |
|
E-Mail : |
|
|
|
|
|
Factory – 2 [ORAL – LIQUID]: |
22, Sec-6A, IIE, SIDCUL, Ranipur, Haridwar - -249403
Uttarakhand INDIA |
|
Tel. No.: |
91-1334-239220 – 24, 325984, 5,6 |
|
Fax No.: |
91-1334-239219 |
|
E-Mail : |
|
|
|
|
|
Factory – 3 [INJECTABLES]
: |
2,3,4,5 Sec-6B, IIE, SIDCUL, Ranipur, Haridwar -249403
Uttarakhand INDIA |
|
Tel. No.: |
91-1334- 237100 – 104 |
|
Fax No.: |
91-1334-237105 |
|
E-Mail : |
DIRECTORS
|
Name : |
Mr. Dharam Chand Jain |
|
Designation : |
Director |
|
Address : |
E -1052, Saraswati Vihar, Delhi -110 034 |
|
Date of Birth/Age : |
28.11.1940 |
|
Date of Appointment : |
19.04.2004 |
|
|
|
|
Name : |
Mr. Sanjeev Jain |
|
Designation : |
Director |
|
Address : |
E -1052, Saraswati Vihar, Delhi -110 034 |
|
Date of Birth/Age : |
11.04.1956 |
|
Date of Appointment : |
19.04.2004 |
|
|
|
|
Name : |
Mr. Mata Pher Singh |
|
Designation : |
Whole Time Director |
|
Address : |
Plot No. 19, 20, 21 Sector 6A, II, E, SIDCUL, Haridwar – 249 403,
Uttaranchal, India |
|
Date of Birth/Age : |
20.06.1957 |
|
Date of Appointment : |
23.05.2004 |
|
|
|
|
Name : |
Mr. Sandeep Jain |
|
Designation : |
Director |
|
Address : |
E -1052, Saraswati Vihar, Delhi -110 034 |
|
Date of Birth/Age : |
05.08.1967 |
|
Date of Appointment : |
19.04.2004 |
|
|
|
|
Name : |
Mr. Rajeev Jain |
|
Designation : |
Director |
|
|
|
|
Name : |
Mr. Narendra Dev Sachdeva |
|
Designation : |
Whole Time Director
|
|
Address : |
40/22, IIIrd Floor, C R Park, Delhi – 110 019 |
|
Date of Birth/Age : |
15.10.1960 |
|
Date of Appointment : |
27.08.2004 |
KEY EXECUTIVES
|
Name : |
Mr Ashok Upendra jha |
|
Designation : |
Secretary |
|
Address : |
48 A, Pocket A -3, Mayur Vihar, Phase – III, Delhi – 110 096 |
|
Date of Birth/Age : |
29.01.1972 |
|
Date of Appointment : |
22.06.2007 |
MAJOR SHAREHOLDERS
/ SHAREHOLDING PATTERN
AS ON 17.07.2006
|
Names of Shareholders |
|
No. of Shares |
|
Mr. Sanjeev Jain |
|
234700 |
|
Mr. Sandeep Jain |
|
264250 |
|
Mr, Kiran Jain |
|
100 |
|
Mrs. Lata Jain |
|
88075 |
|
Mrs Vandana Jain |
|
46550 |
|
Mr D C Jain J / W Arushi Jain |
|
300 |
|
Mr. D C Jain J / W Kanishk Jain |
|
300 |
|
Mrs. Lata Jain J / W Umang
Jain |
|
50 |
|
Mrs. Vandana Jain J/ W Manan Jain |
|
50 |
|
Mr. D C Jain J/ W Sanjeev Jain |
|
65200 |
|
Mr. D C Jain J /W Sandeep Jain |
|
65200 |
|
Mr. Kiran Jain J / W Sanjeev Jain |
|
1750 |
|
Mr. Kiran Jain J/ W Sandeep Jain |
|
1750 |
|
Mr. D C Jain and sons HUF J/W Sanjeev Jain |
|
85000 |
|
Mr. D C Jain and son HUF J/W Sandeep Jain |
|
85000 |
|
Mr. Mata Pher Singh |
|
1250 |
|
Mr. Narendra Dev Sachdeva |
|
1250 |
|
Amazing Research Laboratories
Limited |
|
15000 |
|
Maxcure Drugs and Pharmaceuticals Limited |
|
15000 |
|
Power Pack India |
|
25000 |
|
Life Line India |
|
15000 |
|
Mr. Ajay Kakkar |
|
5000 |
|
Mrs. Ambika Sukumar |
|
2000 |
|
Mr. Balraj Bidaliya |
|
3500 |
|
Mr. Brajesh Sharma |
|
14500 |
|
Mr. Chandra Mohan Khurana |
|
10000 |
|
Mrs Devi Deen Singh |
|
4500 |
|
Mr Gopi Nath Sahu |
|
2000 |
|
Mrs. Kusum Pal |
|
3000 |
|
Mrs. Lalita Rani |
|
1500 |
|
Mrs. Manisha Manocha |
|
1000 |
|
Mrs. Manju Bisht |
|
1000 |
|
Mr Mohan LaL Bansal |
|
1000 |
|
Mr. Partha Sarthi Mohapatra |
|
2000 |
|
Mr. Praveen Soni |
|
2000 |
|
Mr. Rajeshwar Prasad |
|
1000 |
|
Mr. Ramshankar |
|
2000 |
|
Mr. Sudama Prasad |
|
2500 |
|
Mr. Surendra Kumar Saini |
|
1500 |
|
Mr Vijay Pal Singh Rawat |
|
1500 |
|
Sanjeev Jain and Sons HUF |
|
22000 |
|
Sandeep Jain and Sons HUF |
|
33975 |
|
A K Laboratories Limited |
|
46750 |
|
Total |
|
1175000 |
Equity Shares Breakup (Percentage of Total Equity):
[AS ON 31.10.2007]
|
Category |
Percentage |
|
Foreign Holdings |
5.26 |
|
Bodies corporate |
94.74 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer and Supplier of Pharmaceutical Machinery. |
GENERAL
INFORMATION
|
No. of Employees : |
300 |
|
|
|
|
Bankers : |
· State Bank of India Address: Industrial Estate , Wazirpur, Delhi - 110052 · ICICI Bank Limited Address: Land Markrace Cource Circle, Alkapuri, Baroda – 390 015,
Gujarat, India |
|
|
|
|
Banking
Relations : |
Satisfactory |
|
|
|
|
Auditors : |
|
|
Name : |
Anil Jain D.D and Company Chartered Accountants |
|
Address : |
611, Surya Kiran Building, 19 Kasturba Gandhi Marg, New Delhi -110 001 |
|
|
|
|
Associates/Subsidiaries : |
|
CAPITAL STRUCTURE
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
1200000 |
Equity shares |
Rs. 10/- each |
Rs. 12.000 millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
1175000 |
Equity shares |
Rs.10/- each |
Rs. 11.750
millions |
FINANCIAL DATA
[all figures are in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
01.04.2006 to 31.03.2007 |
01.04.2005 to 31.03.2006 |
19.04.2004 to 31.03.2005 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
11.750 |
11.750 |
11.750 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
830.656 |
408.658 |
30.316 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
842.406 |
420.408 |
42.066 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
709.675 |
96.247 |
79.561 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
709.675 |
96.247 |
79.561 |
|
|
DEFERRED TAX LIABILITIES |
15.689 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
1567.770 |
516.655 |
121.627 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
347.084 |
260.325 |
87.820 |
|
|
Capital work-in-progress |
599.811 |
31.799 |
2.978 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.500 |
0.000 |
0.000 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
520.809
|
175.184 |
66.740 |
|
|
Sundry Debtors |
487.363
|
296.175 |
73.213 |
|
|
Cash & Bank Balances |
45.861
|
8.985 |
6.412 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
162.389
|
72.002 |
4.687 |
|
Total
Current Assets |
1216.422
|
552.346 |
151.052 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Current Liabilities |
547.251
|
287.920 |
118.169 |
|
|
Provisions |
48.796
|
39.895 |
2.054 |
|
Total
Current Liabilities |
596.047
|
327.815 |
120.223 |
|
|
Net Current Assets |
620.375
|
224.531 |
30.829 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
1567.770 |
516.655 |
121.627 |
|
PROFIT & LOSS
ACCOUNT
|
PARTICULARS |
01.04.2006 to 31.03.2007 |
01.04.2005 to 31.03.2006 |
19.04.2004 to 31.03.2005 |
|
|
Sales Turnover |
2813.585 |
1942.749 |
162.458 |
|
|
Other Income |
22.972 |
18.805 |
0.000 |
|
|
Total Income |
2836.557 |
1961.554 |
162.458 |
|
|
|
|
|
|
|
|
Profit/(Loss) Before Tax |
432.057 |
385.407 |
21.120 |
|
|
Provision for Taxation |
57.130 |
38.039 |
2.053 |
|
|
Profit/(Loss) After Tax |
374.927 |
347.368 |
19.067 |
|
|
|
|
|
|
|
|
Expenditures : |
|
|
|
|
|
|
Raw Material Consumed |
2166.612 |
1456.293 |
123.548 |
|
|
Salaries, Wages, Bonus, etc. |
128.651 |
62.162 |
2.533 |
|
|
Managerial Remuneration |
0.584 |
0.365 |
0.000 |
|
|
Payment to Auditors |
0.084 |
0.056 |
0.017 |
|
|
Interest |
13.815 |
5.954 |
1.399 |
|
|
Insurance Expenses |
3.294 |
2.013 |
0.086 |
|
|
Power & Fuel |
28.332 |
16.297 |
1.961 |
|
|
Depreciation & Amortization |
12.667 |
5.787 |
0.000 |
|
|
Other Expenditure |
50.461 |
27.218 |
11.796 |
|
Total Expenditure |
2404.500 |
1576.145 |
141.340 |
|
KEY RATIOS
|
PARTICULARS |
|
01.04.2006 to 31.03.2007 |
01.04.2005 to 31.03.2006 |
19.04.2004 to 31.03.2005 |
|
PAT / Total Income |
(%) |
13.22
|
17.70 |
11.73 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
15.36
|
19.83 |
13.00 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
27.63
|
45.63 |
8.73 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.51
|
0.91 |
0.50 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
1.55
|
1.00 |
4.74 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.04
|
1.68 |
1.25 |
LOCAL AGENCY FURTHER
INFORMATION
HISTORY:-
Company was incorporated on 19.04.2004 vide Certificate of incorporation
No. U24239DL2004PLC125888 and obtained its Certificate of Commencement of Business
dated 13.05.2005 from Registrar of Companies NCT of Delhi and Haryana. The
registered Office of the Company is situated at 304, Mohan Place, LSC Block C,
Saraswati Vihar, Delhi – 110 034.
Factory Land at
Haridwar :-
The company got allotment of Industrial Plot No. 19, 20, and 21 Sector -
6 A, Industrial Estate, BHEL Area, Ranipur, Haridwar developed by state
Industrial Development Corporation of Uttaranchal Limited (SIDCUL). Company
took its possession vide letter No. 340/ SIDCUL/GM dated 03.05.2004 and
commenced construction on 21.06.2004.
Form 8
Bankers Charges
Report as per Registry
|
Corporation identity number or foreign company registrations number of
the company |
U24239DL2004PLC125888 |
|
Name of the company |
AKUMS DRUGS AND PHARMACEUTICALS LIMITED |
|
Address |
304, Mohan Place, LSC Block – C, Saraswati
Vihar, New Delhi – 110 034, Delhi, |
|
This Form is for |
Creation of Charge |
|
Type of Charges |
Movable Property |
|
Particular of the charge holder
|
ICICI Bank Limited Address: Land Markrace Cource Circle,
Alkapuri, Baroda – 390 015, Gujarat, India Email: sudhir@brmco.com
CIN: L65190GJ1994PLC021012 |
|
Nature or description of the instrument creating charge |
Deed of hypothecation |
|
Date of the instrument creating charge |
29.11.2006 |
|
Amount Secure by the charge |
Rs. 200.000 millions |
|
Brief of the principal terms and conditions and extent and operation
of the charge |
Rate on interest: Aggregate of 1.15 per cent per annum (‘Margin”), And 6 month LIBOR Terms of Repayment: Eight (8) Equal semi – annual installment the first such installment
being due on end of eighteen (18) month from the Average Drawdown Date. The final
maturity date for the Facility being 5 years from the Average Drawdown Date Margin: 1.15 per cent per annum Extent and operation of the
charge: First pari passu charge on all the movable fixed assets of the company
situated at the units – II and III at Plot No. 22, Sector – 6A and Plot No.
2,3,4, and 5 Sector – 6B, IIE, BHEL Area, Ranipur, Haridwar, Uttranchal,
India being financed out of the facility, ranking pari passu with State Bank
of India Others: The above limit is taken for term loan for an amount of up to USD 4.38
million (“the Facility”). The Facility is interchangeability with letter of
credit facility to a extent of USD 3.5 millions. The facility amount shall
stand reduced to the extent the company makes any utilization under the Letter
of Credit Facility. |
|
Short particulars of the
Property charged |
Movable fixed assets of the company units
– II and III at Plot No. 22, Sector – 6A and Plot No. 2,3,4 and 5 Sector -6B,
IIE, BHEL Area, Ranipur, Haridwar, Uttranchal, India |
|
Name of the
company |
AKUMS DRUGS AND PHARMACEUTICALS LIMITED |
||||||||||||||||||
|
Presented
By |
State Bank of
India, Industrial Estate, Wazirpur, Delhi |
||||||||||||||||||
|
1) Date and
description of instrument creating the change |
C1, C2, C5 dated 30.08.2004
and agreement of mortgage dated 30.08.2004, Registered on 23.09.2004 |
||||||||||||||||||
|
2) Amount secured
by the charge/amount owing on the securities of charge |
Rs. 22.500
millions |
||||||||||||||||||
|
3) Short
particular of the property charged. If the property acquired is subject to
charge, date of the acquired of the property should be given |
Cash Credit
secured by first charge, by hypothecation, over total current assets of the
company i.e, to say stocks and receivable situated at Bhiwandi Charge to be
created as fixed assets of the company including EM of factory land and
building situated at Plot No. 19,20,21 Sector -6A, IIE BHEL area, Ranipur,
Haridwar, Uttranchal |
||||||||||||||||||
|
4) Gist of the
terms and conditions and extent and operation of the charge. |
Rate of interest 0.75% below SBAR i.e,
9.5% p.a. calculated on products of daily balances chargeable monthly |
||||||||||||||||||
|
5) Name and
Address and description of the person entitled to the charge. |
State Bank of India Address: Industrial Estate , Wazirpur,
Delhi |
||||||||||||||||||
|
6) Date and brief description of instrument
modifying the charge |
Supplemental
agreement of hypothecation CIA, C2A and C5 till dated 05.12.2005 and Form B
for equitable mortgage of property in the name of the company dated
05.12.2005 |
||||||||||||||||||
|
7) Particulars of
modifications specifying the terms and conditions or the extent of operations
of the charge in which modification is made and the details of the
modification. |
Limit increased
from Rs. 22.500 millions to Rs. 132.000 millions as under:-
Extension of charge
over fixed assets of the company including equitable mortgage of property
created by the company of its property situated at Plot No. 19,20,21 Sector -6A, IIE BHEL area, Ranipur, Haridwar,
Uttranchal Cash Credit of Rs. 132.000 millions residual value Rs. 38.800
millions Other terms and conditions |
||||||||||||||||||
AS PER
WEBSITE DETAILS
Overview
Subject is a pioneer pharmaceutical development organization
which gives shape/existence to the perspectives to live a happy and
healthier life.
The organization is in contract manufacturing for more than
150 leading National and Multinational Pharmaceuticals Companies, on third
party/loan license and P to P basis.
At present subject is manufacturing more than 500 formulations
in the form of tablets, capsules (Plain and sustain release), soft gelatin, dry
syrup and Large Volume Parental, Small Volume Parental, Dry Powder
Injections, Pre filled syringe, Eye and Ear drops.
Profile
They belong to a family of more innovative, productive and
rescarch based organization of India known as WELCURE DRUGS and PHARMACEUTICALS
LIMITED, with over 20 years experience in pharmaceutical manufacturing and
trading. The company has entered into an agreement with Advance Medical Care
Inc., New Jersey, U.S.A. for setting up a joint venture facilities in the
plant to provide the technical guidance for pharmaceuticals formulations
through its panel of scientists.
Subject was incorporated in April 2004 by Sh. D.C Jain
Chairman cum Managing Director. , Sh. Sanjeev Jain and Sandeep Jain
as whole time Director.
Subject manufactures more than 500 formulations in the form
of tablets, capsules (Plain and sustain release), soft gelatin, dry syrup and
Large volume preparation, Small Volume Parental, Dry Powder Injections,
Pre filled Syringe, Eye and Ear drops.
With a cherished goal to become and remain the twinkling
star of India. The management is consistently focusing on the goal
of improvement with international quality standards and better
performance. It has located its manufacturing operations at SIDCUL
Haridwar, a city in the state of Uttarakhand, India and its registered office
is in Delhi.
Board
of Director
Shri
D. C. Jain
Shri D. C. Jain, B. Com., LL.B., M.I.L (Hons)., G.D.I.M., M.I.I.A.,
A.M.I.B.M. F.A.S.M., F.C.S., an enthusiastic and optimistic personality
and a man of high perspectives and principles is one of the promoter of the
Company and has over 42 years experience in controlling of manufacturing/
trading business in pharmaceutical formulations/ bulk drugs and in running
companies as top level executives. He has been associated with the
pharmaceutical industry since 1974 and had been on the Board of Directors of
several Companies including:
- Welcure Drugs
and Pharmaceuticals Limited as Managing
Director
- A K.
Laboratories Private Limited
Presently, as Managing Director of Welcure Drugs and
Pharmaceuticals Limited Mr. D. C. Jain, has been handling the Finance,
Taxation, Accounts and Legal aspects of the Company. Under his leadership and
guidance, the Company has attained an enviable position in the pharma market
and has entered into several national and foreign joint-ventures.
Dr.
Sanjeev Jain
Dr. Sanjeev Jain, M.B.B.S (Bio), M.B.A., A.M.I.M.A aged
40 years is a leading businessman with deep rooted pharmaceutical family
background and over 20 years experience in pharmaceutical trade including bulk
drugs and formulations. He has the varied and rich experience of generic
marketing. He has been an approved competent person by Drugs Controller, Delhi
Administration for dealing in drugs and pharmaceuticals in
wholesale.
He has worked as Partner from 24.8.1984 to 31.8.1986 in M/s Welcure
Pharmaceuticals Limited, engaged in pharmaceutical trading business.
Thereafter, on its conversion as Welcure Pharmaceuticals Limited, he
worked as Whole Time Director in the Company from 1.9.1986 to 28.2.1995. Since
1.4.1995 he has been working as whole time Director of Welcure Drugs and
Pharmaceuticals Limited and looking after its sales, marketing and material
procurement. He has been on the Board of Directors of several Companies
including:
- Welcure Drugs
and Pharmaceuticals Limited
- A. K.
Laboratories Limited
- Welcure
Pharmaceuticals Limited
Presently, he is heading the Marketing and Procurement Divisions of Welcure
Drugs and Pharmaceuticals Limited as its Whole time Director. Under his
supervision, the company is manufacturing products for reputed companies like –
Lupin, Intas, Zydus, PCI, Dabur, and is also engaged into marketing of its own
formulations countrywide. His efficiency in Product Development and Launch
makes him valuable for any Generic Company. He has also been efficiently taking
care of all the activities related to the product launch in Generics viz.
packing, rates etc.
Shri Sandeep Jain
Sh. Sandeep Jain, B.Com., LL.B., M.B.A., F.M.S.P.I..,
A.M.I.M.A aged about 39 years, is a successful businessman with more than 20
years of experience in pharmaceuticals and having a track record of running a
profitable pharmaceutical business. He has been an approved competent person by
Drugs controller for dealing in drugs and pharmaceuticals in wholesale.
He begun his carrier as as General Manager from 24.8.1984 to
31.8.1986 of M/s Welcure Pharmaceuticals Limited, a partnership concern,
engaged in pharmaceutical trading business. Thereafter, on its conversion as
Welcure Pharmaceuticals Limited, he worked as Whole Time Director in the
Company from 1.9.1986 to 30.7.1994. Since 1.8.1994, he is Whole time Director
of Welcure Drugs and Pharmaceuticals Limited looking after production and
quality control. He has been on the Board of Directors of several Companies
including:
- Welcure Drugs and Pharmaceuticals Limited
- A. K. Laboratories Limited
- Welcure Pharmaceuticals Limited
He is Joint Secretary of RAJASTHAN PHARMACEUTICAL
MANUFACTRERS ASSOCIATION. He had been an Executive Member of BHIWADI
MANUFACTURING ASSOCIATION for the two consecutive terms and had been Chairman
for its HEALTH AND WELFARE COMMITTEE. Shri Sandeep Jain has been the Executive
Member of the Managing Committee of PHD CHAMBER and INDUSTRY and has also
served on its various Committees.
He is recipient of Gold Medal for Management, Certificate of Merit, Samaj Shree
Award for Excellence in Management, Outstanding Personalities Award 1998, Best
Citizens of India Award and Man of the Year 1999 Award.
Products
Oral
Doses/Parenterals
Subject is a
Pharmaceutical Development organization give shape/existence to live
Perspective, Happy and Healthier life.
The organization is in contract manufacturing for more than 150 leading
National and Multinational Pharmaceuticals Companies, on third party / loan
license and P to P basis.
Subject is manufacturing more than 500 formulations in the form of
Tablets, Capsules (Plain and Sustain Release),Soft Gelatin Capsules, Dry Syrups
and Large Volume Parenterals , Small Volume Parenterals, Dry Powder Injections,
Pre -filled Syringes, Eye and Ear drops.
Different Categories of Dosage forms which they are
manufacturing are Describe as under:--
ORAL DOSAGE FORM
|
GENERAL |
PENICILLIN |
CEPHALOSPORIN |
|
Tablets |
Tablets |
Tablets |
|
Dry Powder Solution |
Dry Powder Solution |
Dry Powder Solution |
|
Sachets for Oral Solution |
---- |
---- |
|
Capsules |
Capsules |
Capsules |
|
Soft-Gelatin Capsules |
---- |
---- |
|
Oral-Liquid |
---- |
---- |
PARENTERALS
|
DOSAGE FORM |
DESCRIPTION |
|
Dry Powder Injection |
Penicillin |
|
Dry Powder Injection |
Cephalosporin |
|
Liquid-Ampoules |
1 to 5 ml |
|
Liquid-Vials |
2 to 30ml |
|
FFS |
5 to 100 ml |
|
Pre-Filled Syringes |
---- |
|
Eye and Ear Drops |
---- |
Presently they are Manufacturing More Than 500 Formulations
covering various Pharmacological Categories which are Tabulated as under:--
|
Anti-Inflammatory, Analgesics and Antipyretics |
Anti-Malarial |
Multivitamin-Mineral and Anti-oxidants |
|
Anti-Emetics, Sedatives
and Tranquillizers |
Anthelmintics |
Nutritional Supplements |
|
Anti-Allergic and Decongestants |
Cardiovascular Drugs |
|
|
Anti-Bacterial and Antibiotics |
Cough and Cold Preparations |
---- |
|
Antacids and Anti-Ulcerates |
Gastro-Intestinal and Anti-Diarrheas |
Capsules |
|
Anti-Diabetics |
Haemostatic |
---- |
|
Anti-Fungal |
Haematinics |
---- |
CMT REPORT (Corruption,
Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts, India Prisons Service,
Interpol, etc.
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals have
been formally charged or convicted by a competent governmental authority for
any financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE
GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.42.28 |
|
UK Pound |
1 |
Rs.82.79 |
|
Euro |
1 |
Rs.65.69 |
SCORE & RATING
EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
7 |
|
OPERATING SCALE |
1~10 |
8 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
9 |
|
--PROFITABILIRY |
1~10 |
7 |
|
--LIQUIDITY |
1~10 |
9 |
|
--LEVERAGE |
1~10 |
9 |
|
--RESERVES |
1~10 |
9 |
|
--CREDIT LINES |
1~10 |
9 |
|
--MARGINS |
-5~5 |
--- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
72 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|